Skip to content

Role of the ANS Dysregulation in the Persistence of Fatigue in Rheumatoid Arthritis Patients Treated With Anti-TNF

Role of the Sympathetic Nervous System (ANS) Dysregulation in the Persistence of Fatigue in Rheumatoid Arthritis Patients Treated With Anti-TNF (Tumor Necrosis Factor) - a Monocentric Cross-sectional Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02475486
Acronym
ANSRA
Enrollment
50
Registered
2015-06-18
Start date
2016-02-25
Completion date
2018-10-08
Last updated
2019-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

Rheumatoid Arthritis, sympathetic nervous system, SNA, fatigue

Brief summary

Despite the large therapeutic arsenal available since one decade allowing a strong reduction of inflammation process, rheumatoid arthritis (RA) patients claimed pain, fatigue, sleep problems and other quality of life outcomes. Fatigue reduction during TNF blockers therapy is lower than the strong reduction in RA disease activity. Furthermore, RA patients have higher prevalence of non-inflammatory pain than general population. Fatigue is a real major problem due to 50% of patients considered it as severe. This dissociation between disease activity and fatigue level suggests that fatigue is multifactorial. No consistent explanations for fatigue are currently available.

Interventions

DEVICEVistaO2

ANS (sympathetic nervous system) parameters are measured by VistaO2 device in RA patients

Sponsors

Pfizer
CollaboratorINDUSTRY
Centre Hospitalier Universitaire de Saint Etienne
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

: * RA diagnosis according to ACR/EULAR 2010 * RA with low disease activity according to DAS28 \< 3.2 * Written consent obtained

Exclusion criteria

: * Other diagnosis than RA * Depression known * Hypertension treated or not, * Diseases interfering with ANS analysis: cardiac arrhythmia, beta-blocker therapy, * Pregnant or breastfeeding women, * Inability to go two consecutive days at the North hospital for the delivery and return of the Vista02 device

Design outcomes

Primary

MeasureTime frameDescription
Ratio low/high frequencies of power spectral density of R-R intervalsday1Comparison of Ratio low/high frequencies of power spectral density of R-R intervals between RA patients with low fatigue and RA patients with high fatigue. Ratio low/high frequencies of power spectral density of R-R is measured by VistaO2 device.

Secondary

MeasureTime frameDescription
Standard deviation of all R-R intervals (SDNN)day 1Comparison of Standard deviation of all R-R intervals (SDNN) between RA patients with low fatigue and RA patients with high fatigue. Standard deviation of all R-R intervals (SDNN) is measured by VistaO2 device.
Total Power spectral density (PSD)day 1Comparison of Total Power spectral density (PSD) between RA patients with low fatigue and RA patients with high fatigue. Total Power spectral density (PSD) is measured by VistaO2 device.
PSD of Lower Frequenciesday 1Comparison of PSD of Lower Frequencies between RA patients with low fatigue and RA patients with high fatigue. PSD of Lower Frequencies is measured by VistaO2 device.
PSD of High Frequenciesday 1Comparison of PSD of High Frequencies between RA patients with low fatigue and RA patients with high fatigue. PSD of High Frequencies is measured by VistaO2 device.
Number of sleep apnea syndromeday 1Comparison of Number of sleep apnea syndrome between between RA patients with low fatigue and RA patients with high fatigue. sleep apnea syndrome is measured by VistaO2 device.
Physical activityday 1Comparison of physical activity between RA patients with low fatigue and RA patients with high fatigue. Physical activity is measured by IPAQ score.
quality of sleepday 1Comparison of quality of sleep between RA patients with low fatigue and RA patients with high fatigue. Quality of sleep is measured by PSQI score.
depressionday 1Comparison of depression level between RA patients with low fatigue and RA patients with high fatigue. Depression is measured by HAD, BDI and HDRS scales.
Correlation between fatigue and Ratio low/high frequencies of power spectral density of R-R intervalsday 1fatigue is measured with a visual analogic scale
normalized value of the High and Low frequenciesday 1Comparison of normalized value of the High and Low frequencies between RA patients with low fatigue and RA patients with high fatigue. normalized value of the High and Low frequencies is measured by VistaO2 device.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026